The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together the medicines regulatory authorities và pharmaceutical industry around the world. ICH aims lớn achieve greater harmonisation worldwide for the development and approval of safe, effective, và high-quality medicines in the most resource-efficient manner. The European Medicines Agency (chungcutuhiepplaza.com), in collaboration with EU thành viên States, supports the European Commission"s membership in ICH and plays a key role in the development and implementation of ICH guidelines​​​​​​ .

Bạn đang xem: Ich guidelines

The Council was officially established on 23 October 2015, after 25 years as the International Conference on Harmonisation. The reformed ICH is intended lớn transform ICH into a truly global initiative supported by a robust và transparent governance structure.

ICH achieves harmonisation through developing guidelines & technical requirements for the development, approval và safety monitoring of medicines involving regulatory and industry experts. ICH regulatory members adopt the guidelines & are expected to lớn implement them.

The objectives and activities of ICH are similar lớn those of the International Cooperation for Harmonisation of Technical Requirements for Pharmaceuticals for Veterinary Medicinal Use (VICH).

For a list of ICH members and observers, see ICH: Membership.

ICH guidelines và technical requirements include:

The results of a survey commissioned by ICH show that the EC and chungcutuhiepplaza.com, in collaboration with EU member States, adequately implement and adhere to ICH guidelines, without introducing unjustified modifications:

These results are part of a 2019 study lớn monitor the adequacy of implementation and adherence to ICH guidelines in regulatory thành viên and observer countries và regions. The study report provides a gap analysis based on authorities’ & companies’ views on the implementation and adherence of regulators to ICH guidelines. It reveals a close alignment between the self-declaration of the authorities and perception among companies. 

For more information, see ICH guideline implementation on the ICH website.

The ICH Assembly và Management Committee include an chungcutuhiepplaza.com representative and the chair of chungcutuhiepplaza.com"s Committee for Medicinal Products for Human Use (CHMP).

chungcutuhiepplaza.com acts as technical coordinator for ICH activities & plays a key role in EU contributions to ICH topics are developed & communicated in a timely manner. European experts nominated by the CHMP participate in the expert working groups that draft the guidelines, and can act as chair or rapporteur responsible for leading the group"s work.

chungcutuhiepplaza.com supports ICH in its efforts to lớn obtain early stakeholder input on a regional basis towards its good clinical practice (GCP) renovation process, by gathering the views và engaging European stakeholders via its Patients" & Consumers" (PCWP) và Healthcare Professionals" (HCPWP) Working Parties

Once an ICH guideline has been finalised, the CHMP is responsible for implementing it as a European guideline. All harmonised guidelines are published on the chungcutuhiepplaza.com trang web on Scientific guidelines: ICH guidelines.

The Agency also sits on the management board of ICH"s Medical Dictionary for Regulatory Activities (MedDRA).

chungcutuhiepplaza.com is supporting ICH"s pilot regional stakeholder engagement approach for the moderinsation of its good clinical practice guidance (ICH E6(R3)), by facilitating the obtaining of the relevant input in Europe via its Patients" & Consumers" (PCWP) & Healthcare Professionals" (HCPWP) Working Parties. The feedback gathered via chungcutuhiepplaza.com in Europe, along with 

chungcutuhiepplaza.com is coordinating the stakeholder engagement process in Europe for the revision of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6 good clinical practice (GCP) guideline.

This is to help ensure that the perspectives of European patients, healthcare professionals và clinical researchers are taken into account during the revision process.

ICH has committed itself lớn engaging stakeholders from the outset of the revision process for this guideline. This aims to lớn ensure that the revised guideline will meet the needs of those conducting or participating in clinical trials.

As a first step, chungcutuhiepplaza.com held a workshop with its Patients" & Consumers" (PCWP) và Healthcare Professionals" (HCPWP) Working Parties in June 2020 to gather their views & experiences. The workshop summary report is available:

For more information on the ICH E6 revision process, see:

chungcutuhiepplaza.com is a co-sponsor of the

ICH reflection paper on patient-focused drug development . This paper identifies key areas where incorporation of the patient’s perspective could improve the quality, relevance, safety and efficiency of drug development & inform regulatory decision making. It also presents opportunities for development of new ICH guidelines lớn provide a globally harmonized approach khổng lồ inclusion of the patient’s perspective in a way that is methodologically sound và sustainable for both regulated industry & regulatory authorities.

Xem thêm: Tính Chất Ba Đường Trung Tuyến, Của Tam Giác (Phần 1)

This reflection paper has been updated as a result of the public consultation process initiated by ICH khổng lồ gather public comments from relevant (non-ICH) stakeholders. Furthermore, when the proposed guideline work advances, this will include plans for further public consultation and engagement.